Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells

Cancer Science

Volumn 99, Issue 8, 2008, Pages 1633-1642

  Demachi Okamura, Ayako ^a   Ito, Yoshinori ^b   Akatsuka, Yoshiki ^a   Tsujimura, Kunio ^c   Morishima, Yasuo ^a   Takahashi, Toshitada ^d   Kuzushima, Kiyotaka ^a,b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Aichi Health Promotion Foundation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; HLA DR ANTIGEN; HLA DR4 ANTIGEN; PEPTIDE VACCINE;

ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DESIGN; DRUG TARGETING; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; EPSTEIN BARR VIRUS; GENE FUNCTION; GENE IDENTIFICATION; GENE MAPPING; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOTHERAPY; LYMPHOBLASTOID CELL LINE; MOLECULAR CLONING; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INFECTION;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL TRANSFORMATION, VIRAL; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES;

EID: 49749097183     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00852.x     Document Type: Article

References (48)

1. Rickinoson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology, 5th edn. Philadelphia: Lippincott, 2006; 2655-700.
2. Kimura H, Hoshino Y, Kanegane H et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001; 98: 280-6.
3. Kieff E, Rickinoson AB. Epstein-Barr virus and its replication. In: Fields BN Knipe DM, Howley PM, eds. Fields Virology, 5th edn. Philadelphia: Lippincott, 2006; 2655-700.
4. Ohno S, Luka J, Lindahl T, Klein G. Identification of a purified complement-fixing antigen as the Epstein-Barr-virus determined nuclear antigen (EBNA) by its binding to metaphase chromosomes. Proc Natl Acad Sci USA 1977; 74: 1605-9.
5. Frappier L, O'Donnell M. Overproduction, purification, and characterization of EBNA1, the origin binding protein of Epstein-Barr virus. J Biol Chem 1991; 266: 7819-26.
6. Lee MA, Diamond ME, Yates JL. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J Virol 1999; 73: 2974-82.
7. Davis JE, Moss DJ. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies. Tissue Antigens 2004; 63: 285-92.
8. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15: 405-31.
9. Khanna R, Burrows SR, Nicholls J et al. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 1998; 28: 451-8.
10. + T lymphocytes. J Exp Med 2004; 199: 459-70.
11. Demachi-Okamura A, Ito Y, Akatsuka Y et al. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies. Eur J Immunol 2006; 36: 593-602.
12. Levitskaya J, Coram M, Levitsky V et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685-8.
13. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997; 94: 12616-21.
14. Lee SP, Brooks JM, Al-Jarrah H et al. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J Exp Med 2004; 199: 1409-20.
15. + T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med 2004; 199: 1421-31.
16. Ito Y, Demachi-Okamura A, Ohta R et al. Full-length EBNA1 mRNA-transduced dendritic cells stimulate cytotoxic T lymphocytes recognizing a novel HLA-Cw*0303- and -Cw*0304-restricted epitope on EBNA1-expressing cells. J General Virol 2007; 88: 770-80.
17. + T cells: When, where, and how. Annu Rev Immunol 2006; 24: 519-40.
18. + T lymphocytes: A critical component of antitumor immunity. Cancer Invest 2005; 23: 413-9.
19. + T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174: 3798-807.
20. +) T-cell response. Nat Rev Immunol 2004; 4: 595-602.
21. + T cells. J Immunol 2006; 177: 6795-803.
22. + T cell to a fully functional tumor killer cell. Cancer Res 2002; 62: 6438-41.
23. + T lymphocytes in an HLA class II-restricted manner. Blood 2005; 106: 1415-8.
24. Jellison ER, Kim SK, Welsh RM. MHC class II-restricted killing in vivo during viral infection. J Immunol 2005; 174: 614-18.
25. +) T-helper 1 responses. J Virol 2001; 75: 8649-59.
26. Landais E, Saulquin X, Scotet E et al. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood 2004; 103: 1408-16.
27. Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 2006; 203: 995-1006.
28. Kelsoe G, Zheng B. Sites of B-cell activation in vivo. Curr Opin Immunol 1993; 5: 418-22.
29. MacLennan IC, Gulbranson-Judge A, Toellner KM et al. The changing preference of T and B cells for partners as T-dependent antibody responses develop. Immunol Rev 1997; 156: 53-66.
30. +) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 2000; 191: 1649-60.
31. + T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes. J Virol 2006; 80: 8263-6.
32. +) Th1 cells kill Burkitt's lymphoma cells. J Immunol 2002; 169: 1593-603.
33. + T cells in the control of mouse Burkitt lymphoma in vivo. J Clin Invest 2004; 114: 542-50.
34. +) T-cell frequencies by flow cytometry. Blood 1999; 94: 3094-100.
35. Zhang Y, Nagata H, Ikeuchi T et al. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol 2003; 121: 805-14.
36. Oyoshi MK, Nagata H, Kimura N et al. Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active Epstein-Barr virus infection. Am J Pathol 2003; 162: 1629-38.
37. Kondo E, Topp MS, Kiem HP et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 2002; 169: 2164-71.
38. Schultze JL, Michalak S, Seamon MJ et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997; 100: 2757-65.
39. Akatsuka Y, Goldberg TA, Kondo E et al. Efficient cloning and expression of HLA class I cDNA in human B-lymphoblastoid cell lines. Tissue Antigens 2002; 59: 502-11.
40. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 1997; 7: 791-802.
41. +) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001; 98: 1872-81.
42. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 1994; 39: 230-42.
43. Rudensky Ayu, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991; 353: 622-7.
44. Khanna R, Burrows SR, Steigerwald-Mullen PM, Thomsom SA, Kurilla MG, Moss DJ. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: Implications for viral persistence and tumor surveillance. Virology 1995; 214: 633-7.
45. Kruger S, Schroers R, Rooney CM, Gahn B, Chen SY. Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother 2003; 26: 212-21.
46. + T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol 2005; 79: 4896-907.
47. +) T cells specific for an MHC class II promiscuous epitope. J Immunol 2002; 169: 2172-9.
48. + EBV-specific CTLs. J Immunol 1997; 158: 3619-25.